论文部分内容阅读
目的 观察３ 种大剂量分割放疗对非小细胞肺癌（ Ｎ Ｓ Ｃ Ｌ Ｃ） 脑转移患者的耐受性及疗效。方法 １９９７ 年１ 月～１９９８ 年１２ 月共治疗 Ｎ Ｓ Ｃ Ｌ Ｃ 脑转移３５ 例，原发灶经病理证实，脑转移灶经 Ｃ Ｔ 和 Ｍ Ｒ Ｉ证实。根据 Ｎ Ｓ Ｃ Ｌ Ｃ 脑转移原发灶状态、转移情况制定３ 种大剂量分割放疗方案。结果 １ 例因癫癎发作终止治疗，３４ 例完成放疗计划。３ 组均无明显急性不良反应，疗效：除１ 例面麻症状改善不明显外，其余患者症状或体征放疗后均得到改善，３ 组无差异。第一组中位生存期２１ 周（２ ．５～７４ 周） ，第二组为２６ ．４ 周（９ ．４ ～９６ 周） ，第三组为３７ ．７ 周（３ ～４３ 周） ，第一组与第三组差异有显著性（ Ｐ＜ ０ ．０５） 。结论 Ｎ Ｓ Ｃ Ｌ Ｃ 脑转移患者能耐受３ 种大分割照射剂量，无明显急性反应，初步疗效显示对有较好预后因素的患者加大放疗剂量可提高中位生存期。
Objective To observe the tolerability and efficacy of three high-dose fractionated radiotherapy for non-small cell lung cancer (NSCLC) brain metastases. Methods From January 1997 to December 1998, 35 cases of NSCLC brain metastases were treated. The primary lesions were confirmed by pathology. Brain metastases were confirmed by C T and M R I. According to NSCLC brain metastases, the status of metastasis, the development of three kinds of high-dose split radiotherapy program. Results One case was terminated due to epileptic seizures and 34 cases completed radiotherapy plans. There was no obvious acute adverse reaction in the three groups. Efficacy: In addition to the improvement of symptoms in one case of facial anesthesia, other patients had improved symptoms or signs after radiotherapy, and there was no difference in the three groups. The median survival time was 21 weeks (2.5 to 74 weeks) in the first group and 26 in the second group. 4 weeks (9. 4 to 96 weeks), the third group is 37. At 7 weeks (3 to 43 weeks), the difference between the first group and the third group was significant (P < 0.05). Conclusion NSCLC patients with brain metastases can tolerate 3 fractional radiation doses without obvious acute response. The preliminary results show that increasing the dose of radiotherapy for patients with better prognostic factors can improve the median survival period.